Copy of Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer
У вашего броузера проблема в совместимости с HTML5
Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.